The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and Zepbound — the brand name of tirzepatide, threatening a workaround that allowed ...

A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight ... dosages slightly different from the standard, FDA-approved amounts or including additives such as vitamins ...